Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours

British Journal of Cancer

Volumn 91, Issue 6, 2004, Pages 1112-1118

  Mora, J ^a,b   Alaminos, M ^a   De Torres, C ^b   Illei, P ^a   Qin, J ^a   Cheung, N K V ^a   Gerald, W L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOSPITAL SANT JOAN DE DÉU   (Spain)

Author keywords

CDKN2A; Microarrays; MTAP; Neuroblastoma; Nuclear factor 1 B3

Indexed keywords

5' METHYLTHIOADENOSINE PHOSPHORYLASE; ALPHA INTERFERON; BETA INTERFERON; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA; PROTEIN P14; PROTEIN P15; PROTEIN P16; UNCLASSIFIED DRUG;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 9P; CONTROLLED STUDY; DNA MICROARRAY; GENE DELETION; GENE EXPRESSION REGULATION; GENE LOCATION; GENE LOCUS; GENE MAPPING; HUMAN; HUMAN CELL; HUMAN TISSUE; NEUROBLASTOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RISK ASSESSMENT; TELOMERE; TRANSCRIPTION REGULATION;

CHROMOSOME MAPPING; CHROMOSOMES, HUMAN, PAIR 9; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DISEASE PROGRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LOSS OF HETEROZYGOSITY; NEOPLASM STAGING; NEUROBLASTOMA; SURVIVAL ANALYSIS;

EID: 5044234412     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602094     Document Type: Article

References (50)

1. Beltinger CP, White PS, Sulman EP, Maris JM, Brodeur GM (1995) No CDKN2 mutations in neuroblastomas. Cancer Res 55: 2053-2055
2. Cairns P, Tokino K, Eby Y, Sidransky D (1994) Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res 54: 1422-1424
3. Castresana JS, Gomez L, Garcia-Miguel P, Queizan A, Pestana A (1997) Mutational analysis of the p16 gene in human neuroblastomas. Mol Carcinog 18: 129-131
4. Chin L, Pomerantz J, DePinho RA (1998) The INK4a/ARF tumor suppressor: one gene - two products - two pathways. Trends Biochem Sci 23: 291-296
5. Cox DR, Oakes D (1984) Analysis of Survival Data. London: Chapman & Hall
6. Diaz MO, Rubin CM, Harden A, Ziemin S, Larson RA, Le Beau MM, Rowley JD (1990) Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 322: 77-82
7. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, Chilcote RR, Rowley JD (1988) Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA 85: 5259-5263
8. Diccianni MB, Chau LS, Batova A, Vu TQ, Yu AL (1996) The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance. Cancer Lett 104: 183-192
9. Easton J, Wei T, Lahti JM, Kidd VJ (1998) Disruption of the cyclin D/cyclin-dependent kinase/INK4/retinoblastoma protein regulatory pathway in human neuroblastoma. Cancer Res 58: 2624-2632
10. Einhorn S, Grander D, Bjork O, Brondum-Nielsen K, Soderhall S (1990) Deletion of alpha-, beta-, and omega-interferon genes in malignant cells from children with acute lymphocytic leukemia. Cancer Res 50: 7781-7785
11. Eymin B, Karayan L, Seite P, Brambilla C, Brambilla E, Larsen CJ, Gazzeri S (2001) Human ARF binds E2F1 and inhibits its transcriptional activity. Oncogene 20: 1033-1041
12. Fitchen JH, Riscoe MK, Dana BW, Lawrence HJ, Ferro AJ (1986) Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors. Cancer Res 46: 5409-5412
13. Garcia-Castellano JM, Villanueva A, Healey JH, Sowers R, Cordon-Cardo C, Huvos A, Bertino JR, Meyers P, Gorlick R (2002) Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma. Clin Cancer Res 8: 782-787
14. Giordani L, Iolascon A, Servedio V, Mazzocco K, Longo L, Tonini GP (2002) Two regions of deletion in 9p22-p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet 135: 42-47
15. Hannon GJ, Beach D (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-261
16. Iolascon A, Giordani L, Moretti A, Tonini GP, Lo Cunsolo C, Mastropietro S, Bordello A, Ragione FD (1998) Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma. Pediatr Res 43: 139-144
17. James CD, He J, Collins VP, Allalunis-Turner MJ, Day III RS (1993) Localization of chromosome 9p homozygous deletions in glioma cell lines with markers constituting a continuous linkage group. Cancer Res 53: 3674-3676
18. Kamatani N, Nelson-Rees WA, Carson DA (1981) Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme. Proc Natl Acad Sci USA 78: 1219-1223
19. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day III RS, Johnson BE, Skolnick MH (1994b) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264: 436-440
20. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Feldhaus J, McIvre M, Aitken JF, Anderson DE, Bergman W, Frauts R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994a) Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 8: 23-26
21. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
22. Kawamata N, Seriu T, Koeffler HP, Bartram CR (1996) Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/ INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. Cancer 77: 570-575
23. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, Reuter V, Gerald WL (2002) Comprehensive gene expression analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506
24. Liu Y, Bernard HU, Apt D (1997) NFI-B3, a novel transcriptional repressor of the nuclear factor I family, is generated by alternative RNA processing. J Biol Chem 272: 10739-10745
25. Lundberg AS, Weinberg RA (1999) Control of the cell cycle and apoptosis. Eur J Cancer 35: 531-539
26. Lydiatt WM, Davidson BJ, Schantz SP, Caruana S, Chaganti RS (1998) 9p21 deletion correlates with recurrence in head and neck cancer. Head Neck Mar 20: 113-118
27. Marshall B, Isidro G, Martins AG, Boavida MG (1997) Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet Cytogenet 96: 134-139
28. Mora J, Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Fazzari M, Heller G, Chen L, Gerald WL (2000) Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn 2: 37-46
29. Mora J, Cheung NKV, Gerald W (2003) Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Lett 197: 119-124
30. Mora J, Cheung NKV, Juan G, Illei P, Cheung I, Chi S, Ladanyi M, Cordon-Cardo C, Gerald WL (2001c) Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res 61: 6892-6898
31. Mora J, Gerald W, Chen L, Qin J, Cheung NKV (2001a) Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer 91: 435-442
32. Mora J, Gerald W, Qin J, Cheung NKV (2002b) Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. Cancer 94: 2756-2765
33. Mora J, Gerald WL, Qin J, Cheung NKV (2001b) Molecular genetics of neuroblastoma and the implications for clinical management. A review of the MSKCC experience. The Oncologist 6: 263-268
34. Mora J, Oplanic S, Chen L, Cheung NKV, Gerald W (2002a) Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Res 62: 1761-1767
35. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756
36. Olopade OI, Buchhagen DL, Malik K, Sherman J, Nobori T, Bader S, Nau MM, Gazdar AF, Minna JD, Diaz MO (1993) Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res 53: 2410-2415
37. Olopade OI, Pomykala HM, Hagos F, Sveen LW, Espinosa III R, Dreyling MH, Gursky S, Stadler WM, Le Beau MM, Bohlander SK (1995) Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci USA 92: 6489-6493
38. Omura-Minamisawa M, Diccianni MB, Chang RC, Batova A, Bridgeman LJ, Schiff J, Cohn SL, London WB, Yu AL (2001) p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease. Clin Cancer Res 7: 3481-3490
39. Pomerantz J, Schreiber-Agus N, Liegeois NJ, Silverman A, Alland L, Chin L, Poles J, Chen K, Orlow I, Lee HW, Cordon-Cardo C, DePinho RA (1998) The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 92: 713-723
40. Qian F, Kruse U, Lichter P, Sippel AE (1995) Chromosomal localization of the four genes (NFIA, B, C, and X) for the human transcription factor nuclear factor I by FISH. Genomics 28: 66-73
41. Quelle DE, Zindy F, Ashmun RA, Sherr CJ (1995) Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993-1000
42. Schmid M, Malicki D, Nobori T, Rosenbach MD, Campbell K, Carson DA, Carrera CJ (1998) Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC). Oncogene 17: 2669-2675
43. Serrano M, Hannon GJ, Beach DA (1993) New regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366: 704-707
44. Sharpless NE, DePinho RA (1999) The INK4A/ARF locus and its two gene products. Curr Opin Genet Dev 9: 22-30
45. Spruck III CH, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA (1994) p16 gene in uncultured tumours. Nature 370: 183-184
46. Takita J, Hayashi Y, Kohno T, Shiseki M, Yamaguchi N, Hanada R, Yamamoto K, Yokota J (1995) Allelotype of neuroblastoma. Oncogene 11: 1829-1834
47. Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, Yokota J (1997) Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res 57: 907-912
48. Takita J, Hayashi Y, Nakajima T, Adachi J, Tanaka T, Yamaguchi N, Ogawa Y, Hanada R, Yamamoto K, Yokota J (1998) The p16 (CDKN2A) gene is involved in the growth of neuroblastoma cells and its expression is associated with prognosis of neuroblastoma patients. Oncogene 17: 3137-3143
49. Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS (2001) Homozygous deletion of CDKN2A (p16INK4a/ p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma. Cancer Res 61: 679-686
50. Zhang H, Chen ZH, Savarese TM (1996) Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. Cancer Genet Cytogenet 86: 22-28